vs

Side-by-side financial comparison of COPT DEFENSE PROPERTIES (CDP) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.

COPT DEFENSE PROPERTIES is the larger business by last-quarter revenue ($197.4M vs $170.6M, roughly 1.2× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 20.0%, a 57.2% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 7.6%). COPT DEFENSE PROPERTIES produced more free cash flow last quarter ($288.9M vs $182.8M).

COPT Defense Properties is a real estate investment trust that invests in office buildings, mostly in the suburbs of the Washington, D.C. metropolitan area. It primarily leases to the U.S. government or companies in the arms industry. As of December 31, 2024, the company owned 164 office buildings comprising 16.5 million square feet and 31 single-tenant data centers comprising 5.9 million square feet.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.

CDP vs PTGX — Head-to-Head

Bigger by revenue
CDP
CDP
1.2× larger
CDP
$197.4M
$170.6M
PTGX
Growing faster (revenue YoY)
PTGX
PTGX
+176.8% gap
PTGX
184.4%
7.6%
CDP
Higher net margin
PTGX
PTGX
57.2% more per $
PTGX
77.2%
20.0%
CDP
More free cash flow
CDP
CDP
$106.1M more FCF
CDP
$288.9M
$182.8M
PTGX

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
CDP
CDP
PTGX
PTGX
Revenue
$197.4M
$170.6M
Net Profit
$39.4M
$131.7M
Gross Margin
Operating Margin
19.9%
74.3%
Net Margin
20.0%
77.2%
Revenue YoY
7.6%
184.4%
Net Profit YoY
8.0%
381.7%
EPS (diluted)
$0.32
$2.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDP
CDP
PTGX
PTGX
Q4 25
$197.4M
Q3 25
$188.8M
Q2 25
$189.9M
Q1 25
$187.9M
Q4 24
$183.4M
$170.6M
Q3 24
$189.2M
Q2 24
$187.3M
Q1 24
$193.3M
$255.0M
Net Profit
CDP
CDP
PTGX
PTGX
Q4 25
$39.4M
Q3 25
$43.7M
Q2 25
$40.2M
Q1 25
$36.2M
Q4 24
$36.5M
$131.7M
Q3 24
$37.4M
Q2 24
$36.4M
Q1 24
$33.7M
$207.3M
Operating Margin
CDP
CDP
PTGX
PTGX
Q4 25
19.9%
Q3 25
22.5%
Q2 25
21.0%
Q1 25
19.1%
Q4 24
19.7%
74.3%
Q3 24
19.8%
Q2 24
19.4%
Q1 24
17.5%
80.9%
Net Margin
CDP
CDP
PTGX
PTGX
Q4 25
20.0%
Q3 25
23.2%
Q2 25
21.1%
Q1 25
19.3%
Q4 24
19.9%
77.2%
Q3 24
19.8%
Q2 24
19.4%
Q1 24
17.4%
81.3%
EPS (diluted)
CDP
CDP
PTGX
PTGX
Q4 25
$0.32
Q3 25
$0.37
Q2 25
$0.34
Q1 25
$0.31
Q4 24
$0.31
$2.01
Q3 24
$0.32
Q2 24
$0.31
Q1 24
$0.29
$3.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDP
CDP
PTGX
PTGX
Cash + ST InvestmentsLiquidity on hand
$275.0M
$418.9M
Total DebtLower is stronger
$2.8B
Stockholders' EquityBook value
$1.5B
$675.3M
Total Assets
$4.7B
$744.7M
Debt / EquityLower = less leverage
1.83×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDP
CDP
PTGX
PTGX
Q4 25
$275.0M
Q3 25
$23.7M
Q2 25
$21.3M
Q1 25
$24.3M
Q4 24
$38.3M
$418.9M
Q3 24
$34.5M
Q2 24
$100.4M
Q1 24
$123.1M
$322.6M
Total Debt
CDP
CDP
PTGX
PTGX
Q4 25
$2.8B
Q3 25
$2.4B
Q2 25
$2.4B
Q1 25
$2.4B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Q1 24
$2.4B
Stockholders' Equity
CDP
CDP
PTGX
PTGX
Q4 25
$1.5B
Q3 25
$1.5B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.5B
$675.3M
Q3 24
$1.5B
Q2 24
$1.5B
Q1 24
$1.5B
$560.4M
Total Assets
CDP
CDP
PTGX
PTGX
Q4 25
$4.7B
Q3 25
$4.4B
Q2 25
$4.3B
Q1 25
$4.3B
Q4 24
$4.3B
$744.7M
Q3 24
$4.2B
Q2 24
$4.2B
Q1 24
$4.2B
$629.3M
Debt / Equity
CDP
CDP
PTGX
PTGX
Q4 25
1.83×
Q3 25
1.62×
Q2 25
1.63×
Q1 25
1.62×
Q4 24
1.60×
Q3 24
1.61×
Q2 24
1.61×
Q1 24
1.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDP
CDP
PTGX
PTGX
Operating Cash FlowLast quarter
$309.9M
$184.2M
Free Cash FlowOCF − Capex
$288.9M
$182.8M
FCF MarginFCF / Revenue
146.4%
107.1%
Capex IntensityCapex / Revenue
10.7%
0.8%
Cash ConversionOCF / Net Profit
7.87×
1.40×
TTM Free Cash FlowTrailing 4 quarters
$501.5M
$101.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDP
CDP
PTGX
PTGX
Q4 25
$309.9M
Q3 25
$68.6M
Q2 25
$87.9M
Q1 25
$72.1M
Q4 24
$331.0M
$184.2M
Q3 24
$65.1M
Q2 24
$93.8M
Q1 24
$71.0M
$-27.4M
Free Cash Flow
CDP
CDP
PTGX
PTGX
Q4 25
$288.9M
Q3 25
$62.9M
Q2 25
$84.5M
Q1 25
$65.1M
Q4 24
$299.6M
$182.8M
Q3 24
$61.0M
Q2 24
$88.4M
Q1 24
$57.9M
$-27.7M
FCF Margin
CDP
CDP
PTGX
PTGX
Q4 25
146.4%
Q3 25
33.3%
Q2 25
44.5%
Q1 25
34.7%
Q4 24
163.3%
107.1%
Q3 24
32.3%
Q2 24
47.2%
Q1 24
30.0%
-10.9%
Capex Intensity
CDP
CDP
PTGX
PTGX
Q4 25
10.7%
Q3 25
3.0%
Q2 25
1.8%
Q1 25
3.7%
Q4 24
17.1%
0.8%
Q3 24
2.1%
Q2 24
2.9%
Q1 24
6.8%
0.1%
Cash Conversion
CDP
CDP
PTGX
PTGX
Q4 25
7.87×
Q3 25
1.57×
Q2 25
2.19×
Q1 25
1.99×
Q4 24
9.08×
1.40×
Q3 24
1.74×
Q2 24
2.58×
Q1 24
2.11×
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons